Welcome to our dedicated page for SiNtx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on SiNtx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
SINTX Technologies (SINT) announced a company-sponsored Orthopedics This Week Masterclass titled “Silicon Nitride in Orthopedics,” now available as an educational program for industry professionals.
The online session brings together three experts in implant retrieval, biomaterials and clinical practice to examine the science, clinical experience and potential advantages of medical-grade silicon nitride compared with legacy implant materials such as PEEK and titanium. The Masterclass discusses surface chemistry, reported bone-cell response, antibacterial characteristics, and potential applications in composites and 3D printing. SINTX highlights its SiNERGY biocomposite platform for sutures, mesh and wound dressings, and frames the event as part of its shift toward a commercially focused medical device organization in multiple orthopedic markets.
SINTX Technologies (SINT) will present at the 28th Annual H.C. Wainwright Global Investment Conference from September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.
Chief Investment Officer Gregg Honigblum and President Ryan Elmore will deliver a company presentation and hold one-on-one meetings with investors. The presentation is expected to cover progress in commercializing the FDA-cleared SINAPTIC® Foot & Ankle Implant System, expansion of proprietary silicon nitride technology adoption, growth in contract manufacturing activities, and strategic initiatives to broaden commercial opportunities and support long-term shareholder value.
Investors can request meetings through their H.C. Wainwright representative, email meetings@hcwco.com, or contact SINTX Investor Relations at IR@sintx.com.
SINTX Technologies (NASDAQ: SINT) announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders’ equity of $2.5 million for companies listed on the Nasdaq Capital Market. Nasdaq’s decision is based on SINTX’s Form 10-Q for the quarter ended June 30, 2026, which reported stockholders’ equity of approximately $4.83 million. Nasdaq confirmed that the previously disclosed stockholders’ equity deficiency matter is now closed. Management stated that resolving this listing issue supports SINTX’s efforts to strengthen the company while it focuses on commercializing its silicon nitride technologies, expanding its distribution network, and pursuing strategic partnerships aimed at supporting future revenue growth in its medical and advanced ceramics businesses.
SINTX Technologies (NASDAQ: SINT) issued a mid‑year 2026 business update alongside its Q2 10‑Q, emphasizing a shift from technology development toward commercial execution. The company advanced the FDA‑cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System through a Limited Use Release and built an initial network of twelve independent foot‑and‑ankle distributors in the U.S.
SINTX reported approximately $3.2 million in new industrial ceramics purchase orders, with revenue recognition expected to begin in Q3 2026, subject to delivery and acceptance. The company currently expects total revenue of $0.9–$1.1 million in Q3 2026 and $1.0–$1.3 million in Q4 2026.
During the first half, SINTX completed construction of an advanced 3D printing facility for SiNERGY™ patient‑specific silicon nitride/PEEK implants and secured an additional 12‑month period to access roughly $745,000 remaining on a National Institutes of Health grant. It also raised about $5.0 million in gross proceeds via a private placement and At‑The‑Market sales, initiated cost‑management efforts, engaged Southern Metrics to evaluate strategic opportunities, and gained Buy‑rated equity research coverage from H.C. Wainwright & Co. and Maxim Group.
SINTX Technologies (NASDAQ: SINT) will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close, and host a conference call and webcast at 4:30 p.m. ET to review quarterly performance.
The call will feature CEO and Chairman Eric Olson and CFO Kevin Trask. Investors can join via a live webcast on the company’s investor relations site or by telephone after advance registration. A replay will be available on the Events & Webcasts page.
SINTX Technologies (NASDAQ: SINT) has engaged Southern Metrics Consulting, led by CEO and SINTX director Chris Lyons, to establish and manage a new Strategic Opportunity Management Program aimed at identifying, evaluating, and pursuing strategic opportunities to support long-term growth and enhance stockholder value.
Working with SINTX’s executive team and Board, Southern Metrics will help assess potential commercial partnerships, licensing deals, strategic investments, joint ventures, acquisitions, divestitures, and other corporate development initiatives. SINTX views this as a key step in its evolution from an advanced biomaterials developer toward a commercial-stage medical technology company leveraging its silicon nitride platforms and FDA-cleared SINAPTIC Foot & Ankle Implant System.
SINTX Technologies (NASDAQ:SINT) received more than $3.2 million in aggregate purchase orders from multiple contract manufacturing customers for advanced ceramic components. The orders come from several existing relationships, with production and shipments expected to start in the second half of 2026 and extend into 2027.
SINTX Technologies (NASDAQ:SINT) entered securities purchase agreements for a $4.5 million private placement priced at-the-market under Nasdaq rules, issuing 1,882,845 common shares plus Class A and Class B warrants.
Together with a recent $0.5 million ATM sale, SINTX raised about $5.0 million for working capital, commercialization, business development and other strategic uses.
SINTX Technologies (NASDAQ:SINT) will present at the LD Micro Invitational XVI Conference in Los Angeles at the Luxe Sunset Blvd Hotel.
Management plans to discuss commercialization progress, product development, and manufacturing initiatives for its silicon nitride biomaterials platform and will hold one-on-one investor meetings. A live webcast will be available.
SINTX Technologies (NASDAQ: SINT) reported clinical, operational, and leadership milestones positioning the company for commercialization and revenue growth in 2026. Key items include first human implant of the FDA 510(k)-cleared SINAPTIC Foot & Ankle Osteotomy Wedge System, a ~$10 million capital raise, and the appointment of Ryan Elmore as President.
The company completed strategic divestitures, acquired SiNAPTIC Surgical, expanded its patent estate into antipathogenic textiles, executed a supply agreement with Evonik, and initiated preclinical studies for sutures, meshes, and wound care.